Composition for treating hepatitis B and application thereof
Through the compatibility of traditional Chinese medicine compositions and modern pharmaceutical technology, the problems of anti-HBV drugs being sensitive and adverse reactions to drug resistance mutations have been solved, short-term therapeutic effects and safety have been achieved, and economic burden has been reduced.
Patent Information
- Application Number
- CN202411068072.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-19
AI Technical Summary
Existing anti-HBV drugs are sensitive to drug-resistant mutations and are prone to adverse reactions. They require long-term medication, resulting in unsatisfactory treatment results and financial burden.
Provided is a composition for treating hepatitis B, including Poria cocos, Schisandra chinensis, Atractylodes, Cangnus, Licorice, Bupleurum, Astragalus, Salvia miltiorrhiza, Angelica sinensis, Hakka, White Peony, Mulberry Leaf, Pueraria root, Shengma, and Manjing Chinese medicinal materials such as seeds and gentian grass, intermediate extracts are prepared by decoction, soaking, permeation, reflux, water vapor extraction, etc., and tablets, granules, decoctions, oral administration are prepared by combining macroporous resin adsorption separation and evaporation drying technology. liquid or other dosage form.
This composition can significantly reduce the conversion of HBsAg to negative, promote anti-HBs to positive, short treatment cycle, safe and reliable, no adverse reactions were found, low cost, and significant treatment effect.
Abstract
Description
Technical Field
[0001] The embodiments of the present invention relate to the technical field of traditional Chinese medicine, and specifically to a composition for treating hepatitis B and application thereof. Background Art
[0002] my country is one of the countries with a high incidence of HBV infection. About 120 million people carry HBV DNA and become chronic HBV carriers. There are also about 7 million people in serious clinical conditions due to liver decompensation. The annual mortality rate caused by HBV is as high as more than 300,000. According to WHO statistics, one in eight adults in the world is infected with HBV, and nearly one-third of people will be infected with other pathogens such as HBV or HCV in their lifetime. It is estimated that 65 million people die from these diseases. Hepatitis B is characterized by a slow onset, with subclinical and chronic types being more common. Those with persistent HBsAg positive without icterus are prone to chronicity. It is mainly transmitted through blood, mother-to-child and sexual contact.
[0003] Currently, there is no technology that can turn HBsAg (hepatitis B surface antigen) negative and anti-HBs (hepatitis B surface antibody, HBsAb) positive. The only way to control the hepatitis B virus is through antiviral drugs, which require lifelong medication. Current anti-HBV drugs mainly include three types: interferon, nucleoside analogs and protease inhibitors. However, existing anti-HBV drugs have disadvantages: (1) they are sensitive to drug-resistant mutations; (2) they are prone to adverse reactions, such as renal damage, osteoporosis, increased blood sugar, dyslipidemia and other problems; (3) they require long-term medication and cause more side effects, which brings great pain to patients and creates economic burden and mental stress. Therefore, finding new therapeutic drugs is of great significance to reducing the harm caused by viral diseases to the human body. Summary of the invention
[0004] To this end, an embodiment of the present invention provides a composition for treating hepatitis B and its application, so as to solve the problems in the prior art of being sensitive to drug-resistant mutations, easily causing adverse reactions, and requiring long-term medication due to imperfect technology for treating hepatitis B.
[0005] In order to achieve the above purpose, the embodiment of the present invention provides the following technical solutions:
[0006] According to a first aspect of an embodiment of the present invention, the present invention provides a composition for treating hepatitis B, the composition comprising the following raw materials by weight: 10-25 parts of Poria cocos, 5-15 parts of Schisandra chinensis, 5-15 parts of Atractylodes macrocephala, 15-30 parts of Creeping Herb, 10-20 parts of Licorice, 5-15 parts of Bupleurum chinense, 15-30 parts of Astragalus membranaceus, 15-30 parts of Salvia miltiorrhiza, 10-20 parts of Angelica sinensis, 10-20 parts of Scutellaria barbata, 10-20 parts of White Peony Root, 3-8 parts of Mulberry Leaf, 3-8 parts of Pueraria lobata, 3-8 parts of Cimicifuga heracleifolia, 3-8 parts of Vitex rotundifolia, 3-8 parts of Gentiana scabra, and 9-24 parts of auxiliary materials;
[0007] The auxiliary materials include 3-8 parts of powdered sugar, 3-8 parts of dextrin, and 3-8 parts of maltose;
[0008] The dosage form of the composition includes tablets, granules, pills, powders, oral liquids, and decoctions;
[0009] The preparation method of the composition comprises the following steps: grinding the raw materials into powder, preparing the intermediate extract, separating and purifying, evaporating and drying;
[0010] The preparation of the intermediate extract includes the following methods: decoction method, soaking method, permeation method, reflux method, steam method, supercritical fluid extraction method, auxiliary extraction method;
[0011] The separation and purification include the following methods: solid-liquid separation method, water-alcohol method, adsorption clarification method, macroporous resin adsorption separation method, membrane separation method;
[0012] The evaporation and drying include but are not limited to the following methods: normal pressure method, reduced pressure method, thin film evaporation method, reduced pressure drying, spray drying, and freeze drying.
[0013] Furthermore, the preparation of the tablet of the composition comprises the following steps:
[0014] S1: Grind all raw materials into powder;
[0015] S2: Preparation of intermediate extract: add 3.5 times the amount of 95% ethanol solution to the raw material for the first time, reflux for 1.5 hours, filter, recover ethanol from the filtrate, and concentrate to an extract with a relative density of 1.35-1.39; add 5 times the amount of 50% ethanol solution to the extract for the second time, reflux for 1.5 hours, filter; add 5 times the amount of water for the third time, reflux for 2 hours, filter; combine the second and third filtrates, recover ethanol, concentrate to a relative density of 1.20, dilute with water to 0.5g / ml, let stand overnight, filter, and dry the filter residue to obtain the intermediate extract;
[0016] S3: separation and purification: add 6 times the amount of 50% ethanol solution to the intermediate extract, extract 3 times, 2.5 hours each time, filter, recover ethanol from the filtrate, and when concentrated to a certain relative density, select HPD-100 macroporous adsorption resin, adjust the concentration of the loading solution to 17 mg / ml, use 80% ethanol solution as the eluent, and recover ethanol after elution;
[0017] S4: evaporation and drying: the intermediate extract and an appropriate amount of auxiliary materials are mixed to form granules, dried, borneol is ground into fine powder, mixed with the granules, tableted, and coated to obtain the composition tablets.
[0018] Further, the tablets include whole raw drug powder tablets, semi-diffuse paste tablets and whole extract tablets;
[0019] Grind all raw materials into medicinal powder, hereinafter referred to as medicinal powder;
[0020] The preparation method of the whole raw medicinal powder tablet is as follows:
[0021] The drug powder, starch, microcrystalline cellulose and low-substituted hydroxypropyl cellulose are mixed evenly, an appropriate amount of ethanol or distilled water is added as a wetting agent, and the mixture is stirred evenly to form a soft material, and the soft material is made into granules through a 14-20 mesh screen and dried until the moisture content of the granules is 3-10%, and the drying temperature is controlled at 40-100° C., and then magnesium stearate is added to the dried granules and mixed evenly, and tableting is performed to obtain the whole raw drug powder tablets;
[0022] The preparation method of the semi-diffuse paste tablet is as follows:
[0023] Extracting half of the drug powder with ethanol solutions of 80-95%, 50-70%, and 30-40% respectively, discarding the drug residue, and concentrating the extract under reduced pressure and drying to obtain extract powder; uniformly mixing the extract powder, the other half of the drug powder, starch, low-substituted hydroxypropyl cellulose, and microcrystalline cellulose, and tableting, sugar coating, or film coating to obtain the semi-diffuse paste tablet;
[0024] The preparation method of the full extract tablet is as follows:
[0025] The drug powder is extracted with ethanol solutions with concentrations of 80-95%, 50-70%, and 30-40%, respectively, and the drug residue is discarded. The extract is concentrated under reduced pressure and dried to obtain extract powder; the extract powder, starch, low-substituted hydroxypropyl cellulose, and microcrystalline cellulose are evenly mixed, and the whole extract tablets are obtained by tableting, sugar coating, or film coating.
[0026] Furthermore, the preparation of the intermediate extract of the composition decoction includes the following steps: adding 6 times the amount of 70% ethanol solution to the raw material, reflux extraction 3 times, each time for 1.5 hours, filtering, recovering ethanol from the filtrate, and concentrating to a certain relative density, purifying with HPD-100 type macroporous adsorption resin, first eluting with 1BV water, and then eluting with 5BV30% ethanol solution, recovering ethanol from the eluate to obtain the first extract; adding 12 times the amount of water, decocting and extracting 3 times, each time for 0.5 hours, decoction concentrated to an appropriate amount under reduced pressure, adding ethanol to make the alcohol content reach 65%, standing overnight, filtering the filtrate, recovering ethanol, and obtaining the second extract; combining the above two extracts to obtain the intermediate extract of the decoction.
[0027] Furthermore, the preparation of the intermediate extract of the oral liquid of the composition includes the following steps: adding 12 times the amount of water to the raw material, soaking for 1 hour, steam distilling for 8 hours to extract volatile oil, collecting the distillate, filtering the distilled aqueous solution for standby use; soaking the residue in water for 1 hour and then decocting 3 times, each time adding water is 10 times the amount of the medicinal piece, and the decoction time is 1 hour, combining the decoctions, and filtering; heating and refluxing with 8 times the amount of 60% ethanol solution for 2 times, each time for 1 hour, filtering the extract, passing the filtrate through DM-301 macroporous adsorption resin, eluting with 80% ethanol solution as eluent, collecting the eluate, recovering ethanol, combining the above filtrates, and concentrating under reduced pressure to obtain the intermediate extract of the oral liquid.
[0028] Furthermore, the preparation of the intermediate extract of the composition pills includes the following steps: adding 10 times the amount of water to the raw material, soaking for 0.5h, steam distilling for 8h to extract volatile oil, and filtering the medicinal liquid; adding 6 times the amount of water to the medicinal residue after steam distillation, soaking for 0.5h, decocting 3 times, each time for 1h; combining the extracts, filtering, concentrating the filtrate to a relative density of 1.10, adding an appropriate amount of ethanol solution to make the alcohol precipitation concentration of 70%, leaving for 8h, filtering, and recovering ethanol from the filtrate; combining the filtrate with the medicinal liquid after steam distillation, concentrating to a certain volume, concentrating under reduced pressure to a certain relative density, and drying under reduced pressure to obtain the intermediate extract of the pills.
[0029] Furthermore, the preparation method of the granules of the composition comprises the following steps: adding 1500 mg of water to the raw materials, heating to 90-200° C., steaming for 60-90 minutes, then pressurizing to extract the juice, then collecting the paste, adding powdered sugar and dextrin, stirring and drying until the moisture content of the granules is 3-30%, and the drying temperature is controlled at 40-100° C., so as to obtain the granules of the composition.
[0030] According to the second aspect of an embodiment of the present invention, the present invention provides the use of the above-mentioned composition in the preparation of a core antibody drug that promotes the treatment of hepatitis B by converting HBsAg (hepatitis B surface antigen) to negative and anti-HBs (hepatitis B surface antibody, HBsAb) to positive.
[0031] Among them, hepatitis B surface antigen is the outer shell material of hepatitis B virus, which is not contagious itself. HBsAg positivity often indicates the presence of complete virus particles; usually HBsAg positivity can be detected in the serum 2-6 months after infection with the virus, before the serum transaminase rises; most patients with acute hepatitis B can turn negative in the early stage of the disease, but patients with chronic hepatitis B will continue to be positive;
[0032] Hepatitis B surface antibody is an antibody that appears in the recovery period of people who are naturally infected with hepatitis B virus (HBV). At this time, HBsAg has often disappeared naturally. Its existence indicates that people have resistance to hepatitis B. It is an immune and protective antibody against hepatitis B virus in the body. More than 27% of the population in my country has this antibody.
[0033] Hepatitis B e-antigen is produced inside the virus and can be secreted into the blood. A positive e-antigen indicates that the virus is active and is an indicator of infectiousness. The e-antigen is usually tested positive at the same time as the surface antigen is positive after hepatitis B virus infection, or a few days later.
[0034] Hepatitis B e antibody is a protein produced by the human body against e antigen. A positive result indicates that the virus's infectivity has weakened and the disease is in the recovery stage. Positive e antibody appears several months after the antigen turns negative. However, another possibility is that the hepatitis B virus has mutated. At this time, there is no HBeAg in the serum, but anti-HBe can be produced. In this case, HBV-DNA needs to be checked to determine whether the virus still exists.
[0035] There are two types of hepatitis B core antibodies: IgM and IgG. A positive anti-HBc-IgM indicates viral activity and is contagious; a positive anti-HBc-IgG indicates a previous infection, is not contagious, and does not require antiviral treatment. Core antibodies are usually detected in serum 3-5 weeks after the appearance of surface antigens and before the onset of hepatitis B symptoms.
[0036] In addition, HBV-DNA is the genetic gene of the virus and exists in the core part of the virus. Its positivity is basically consistent with HBeAg positivity. Therefore, the effectiveness of the currently recognized antiviral treatment is mainly based on the negative conversion or significant quantitative reduction of HBeAg and HBV-DNA.
[0037] Furthermore, the composition is used in medicine for treating in vitro animal models for studying the mechanism of hepatitis B production.
[0038] The embodiments of the present invention have the following advantages:
[0039] Through the study on compatibility, it is found that the compatibility of the Chinese medicine composition of the present invention is reasonable, and the raw materials synergize with each other to exert therapeutic effects. When used in combination with drugs such as lamivudine, adefovir dipivoxil or entecavir, the therapeutic effect on hepatitis B virus is obvious, the treatment cycle is short, and the recovery rate is high; it is safe and reliable with no adverse reactions found, and will not cause harm to the human body; the ingredients are simple, easy to collect and prepare, and the cost is low and the price is reasonable. DETAILED DESCRIPTION
[0040] The following is a description of the implementation of the present invention by specific embodiments. People familiar with the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0041] The reagents used in the examples are all commercially available.
[0042] Example 1
[0043] The present embodiment provides a composition for treating hepatitis B, which comprises the following raw materials by weight: 15 parts of Poria cocos, 8 parts of Schisandra chinensis, 10 parts of Atractylodes macrocephala, 15 parts of Herba Creepersii, 10 parts of Licorice, 7 parts of Bupleurum chinense, 5 parts of Astragalus, 5 parts of Salvia miltiorrhiza, 15 parts of Angelica sinensis, 15 parts of Scutellaria barbata, 13 parts of White Peony Root, 5 parts of Morus alba, 5 parts of Pueraria lobata, 5 parts of Cimicifuga heracleifolia, 5 parts of Vitex rotundifolia, 5 parts of Gentiana scabra, and 12 parts of auxiliary materials;
[0044] The auxiliary materials include 4 parts of powdered sugar, 4 parts of dextrin and 4 parts of maltose.
[0045] The preparation of the tablet comprises the following steps:
[0046] S1: Grind all raw materials into fine powder and set aside;
[0047] S2: add 3.5 times the weight of the raw material 95% ethanol solution to the powder, reflux for 1.5h, filter, and recover ethanol in the filtrate, and concentrate to an extract with a relative density of 1.39; add 5 times the weight of 50% ethanol solution to the extract for the second time, reflux for 1.5h, filter; add 5 times the weight of water for the third time, reflux for 2h, filter; combine the second and third filtrates, recover ethanol, concentrate to a relative density of 1.20, dilute with water to 0.5g / ml, let stand overnight, filter and dry the filter residue to obtain an intermediate extract;
[0048] S3: Add 6 times the amount of 50% ethanol solution to the intermediate extract, extract 3 times, 2.5 hours each time, filter, recover ethanol from the filtrate, and when concentrated to a certain relative density, select HPD-100 macroporous adsorption resin, adjust the concentration of the loading solution to 17 mg / ml, use 80% ethanol solution as the eluent, and recover ethanol after elution;
[0049] S4: The intermediate extract and the auxiliary materials are mixed to form granules, dried, borneol is ground into fine powder, mixed with the granules, tableted, and coated to obtain the composite tablets.
[0050] Grind all raw materials into medicinal powder, hereinafter referred to as medicinal powder;
[0051] 1) The preparation method of the whole raw medicinal powder tablet is as follows:
[0052] The drug powder, starch, microcrystalline cellulose and low-substituted hydroxypropyl cellulose are mixed evenly, ethanol is added as a wetting agent, and the mixture is stirred evenly to form a soft material. The soft material is made into granules using a 20-mesh screen and dried until the moisture content of the granules is 10%. The drying temperature is controlled at 100° C., magnesium stearate is added and mixed evenly, and tableting is performed to obtain the whole raw drug powder tablets;
[0053] 2) The preparation method of the semi-extract tablet is as follows:
[0054] Extract half of the drug powder with 95%, 70% and 40% ethanol solutions respectively, discard the drug residue, concentrate the extract under reduced pressure and dry it to obtain extract powder; mix the extract powder, the other half of the drug powder, starch, low-substituted hydroxypropyl cellulose and microcrystalline cellulose evenly, press into tablets and coat with sugar to obtain semi-extract tablets;
[0055] 3) The preparation method of the whole extract tablet is as follows:
[0056] The drug powder is extracted with ethanol solutions of concentrations of 95%, 70% and 40% respectively, the drug residue is discarded, and the extract is concentrated under reduced pressure and dried to obtain extract powder; the extract powder, starch, low-substituted hydroxypropyl cellulose and microcrystalline cellulose are evenly mixed, tableted and film-coated to obtain full extract tablets.
[0057] Example 2
[0058] The present embodiment provides a composition for treating hepatitis B, which comprises the following raw materials by weight: 25 parts of Poria cocos, 15 parts of Schisandra chinensis, 15 parts of Atractylodes macrocephala, 30 parts of Herba Crepisae, 20 parts of Licorice, 15 parts of Bupleurum chinense, 30 parts of Astragalus membranaceus, 30 parts of Salvia miltiorrhiza, 20 parts of Angelica sinensis, 20 parts of Scutellaria barbata, 20 parts of White Peony Root, 8 parts of Morus alba, 8 parts of Pueraria lobata, 8 parts of Cimicifuga heracleifolia, 8 parts of Vitex rotundifolia, 8 parts of Gentiana scabra, and 24 parts of auxiliary materials;
[0059] The auxiliary materials include 8 parts of powdered sugar, 8 parts of dextrin and 8 parts of maltose.
[0060] The preparation method comprises the following steps:
[0061] Grind all the raw materials into powder;
[0062] Preparation of the intermediate extract of the composite decoction: add 6 times the amount of 70% ethanol solution to the raw material, reflux extraction 3 times, each time for 1.5 hours, filter, recover ethanol in the filtrate, concentrate to a certain relative density, purify with HPD-100 type macroporous adsorption resin, first elute with 1BV water, then elute with 5BV30% ethanol solution, recover ethanol in the eluate, and obtain the first extract; add 12 times the amount of water, decoct and extract 3 times, each time for 0.5 hours, reduce the pressure and concentrate the decoction to an appropriate amount, add ethanol to make the alcohol content reach 65%, let it stand overnight, filter the filtrate, recover ethanol, and obtain the second extract; combine the above two extracts to obtain the intermediate extract of the decoction.
[0063] The intermediate extract of the decoction is separated and purified by macroporous resin adsorption separation method to obtain the final extract, which is then post-processed and packaged to obtain the composite decoction.
[0064] Example 3
[0065] The present embodiment provides a composition for treating hepatitis B, which comprises the following raw materials by weight: 10 parts of Poria cocos, 5 parts of Schisandra chinensis, 5 parts of Atractylodes macrocephala, 15 parts of Herba Crepisae, 10 parts of Licorice, 5 parts of Bupleurum chinense, 15 parts of Astragalus membranaceus, 15 parts of Salvia miltiorrhiza, 10 parts of Angelica sinensis, 10 parts of Scutellaria barbata, 10 parts of White Peony Root, 3 parts of Morus alba, 3 parts of Pueraria root, 3 parts of Cimicifuga heracleifolia, 3 parts of Vitex rotundifolia, 3 parts of Gentiana scabra, and 9 parts of auxiliary materials;
[0066] The auxiliary materials include 3 parts of powdered sugar, 3 parts of dextrin and 3 parts of maltose.
[0067] Preparation of the intermediate extract of the composite oral liquid: add 12 times the amount of water to the raw material, soak for 1 hour, steam distill for 8 hours to extract volatile oil, collect the distillate, filter the distilled aqueous solution and set aside; soak the residue in water for 1 hour and then decoct for 3 times, each time adding water that is 10 times the amount of the slices, and the decoction time is 1 hour, combine the decoctions, and filter; heat and reflux with 8 times the amount of 60% ethanol solution for 2 times, each time for 1 hour, filter the extract, pass the filtrate through DM-301 macroporous adsorption resin, and elute with 80% ethanol solution as eluent, collect the eluate, recover the ethanol, combine the above filtrates, and concentrate under reduced pressure to obtain the intermediate extract of the oral liquid.
[0068] The intermediate extract of the oral liquid is separated and purified by an adsorption clarification method to obtain a final extract, which is then post-processed and packaged to obtain the oral liquid composition.
[0069] Example 4
[0070] This embodiment provides a composition for treating hepatitis B, and its components are the same as those in Example 1.
[0071] Preparation of the intermediate extract of the composite pill: add 10 times the amount of water to the raw material, soak for 0.5h, steam distill for 8h to extract volatile oil, and filter the medicinal liquid; add 6 times the amount of water to the medicinal residue after steam distillation, soak for 0.5h, and decoct for 3 times, each time for 1h; combine the extracts, filter, and when the filtrate is concentrated to a relative density of 1.10, add an appropriate amount of ethanol solution to make the alcohol precipitation concentration of 70%, let it stand for 8h, filter, and recover ethanol from the filtrate; the filtrate is combined with the medicinal liquid after steam distillation, concentrated to a certain volume, concentrated under reduced pressure to a certain relative density, and dried under reduced pressure to obtain the intermediate extract of the pill.
[0072] The methods used in other steps are the same as those in Example 1.
[0073] Example 5
[0074] This embodiment provides a composition for treating hepatitis B, and its components are the same as those in Example 1.
[0075] The preparation method of the granules comprises the following steps: adding 1500 mg of water to the raw materials, heating to 200°C, steaming for 90 minutes, then squeezing out the juice under pressure, collecting the paste, adding 600 g of sugar powder and 200 g of dextrin, stirring and drying until the moisture content of the granules is 10%, and controlling the drying temperature at 100°C to obtain the composite granules.
[0076] Test Example 1
[0077] 1. Testing standards: HBV-DNA is the genetic gene of the virus and exists in the core part of the virus. Its positive meaning is basically the same as that of HBeAg. Therefore, the effectiveness of the currently recognized antiviral treatment is mainly based on the negative conversion or significant quantitative reduction of HBeAg and HBV-DNA as indicators;
[0078] 1) The first of the five hepatitis B tests is positive, and the other four are negative, indicating that it is the late incubation period of acute viral infection;
[0079] 2) Items 1, 3, and 5 of the five hepatitis B tests are positive, and the remaining two items are negative, commonly known as hepatitis B big three positive, indicating acute or chronic hepatitis B, which is relatively highly contagious;
[0080] 3) Items 1, 4, and 5 of the five hepatitis B tests are positive, and the remaining two items are negative, commonly known as hepatitis B small three positive, indicating acute or chronic hepatitis B, which is relatively weakly contagious;
[0081] 4) The first and third items of the five hepatitis B tests are positive, and the other three items are negative. This indicates that it is the early stage of acute hepatitis B;
[0082] 5) Items 1, 3, 4, and 5 of the five hepatitis B test are positive, indicating that the acute hepatitis B infection is recovering or the patient is a chronic hepatitis B virus carrier;
[0083] 6) If the 1st and 4th items of the five hepatitis B tests are positive and the other three items are negative, it means that the chronic hepatitis B surface antigen carrier is likely to turn negative, or the acute infection is recovering;
[0084] 7) If the 1st and 5th items of the five hepatitis B tests are positive and the other three items are negative, it means acute or chronic hepatitis B, namely: ① acute HBV infection; ② chronic HBsAg carrier; ③ weak infectiousness;
[0085] 8) Item 5 of the five hepatitis B test items is positive, and the other four items are negative, indicating: ① Anti-HBs could not be detected in the previous infection; ② HBsAg has disappeared in the recovery period, and anti-HBs has not yet appeared; ③ Asymptomatic HBsAg carrier;
[0086] 9) Items 2, 4, and 5 of the five hepatitis B tests are positive, and the other two items are negative, indicating that the patient is in the recovery stage of hepatitis B and has immunity;
[0087] 10) If the second item of the five hepatitis B tests is positive and the other four items are negative, it means: ① the person has been vaccinated with hepatitis B vaccine and has produced antibodies and has immunity; ② the person has been infected with hepatitis B virus and has a certain immunity; ③ false positive;
[0088] 11) If the 2nd and 5th items of the five hepatitis B tests are positive and the other three items are negative, it means that the patient has been vaccinated with the hepatitis B vaccine or has recovered from the hepatitis B virus infection and has immunity;
[0089] 12) Items 4 and 5 of the five hepatitis B tests are positive, and the other three are negative, indicating that the patient is in the recovery period of acute hepatitis B virus infection or has been infected with the virus before;
[0090] 13) All five hepatitis B test results are negative, indicating that the person has not been infected with HBV in the past or present, but there is currently no protective antibody.
[0091] 2. Typical cases:
[0092] 1) Patient Li had a hepatitis B test in the hospital and the results showed that items 1, 3, and 5 were positive. The patient took entecavir and the hepatitis B virus was controlled at 1.0×10 3 After taking the composition of Example 1 for 3 months (the dosage is 200 g / d), the hepatitis B two-pair half quantitative test was performed again. The 2nd, 4th and 5th items of the five hepatitis B items were positive, and the other two items were negative, indicating that it was the recovery period of hepatitis B and the patient had immunity.
[0093] 2) Patient Zhang had a hepatitis B test in the hospital and the results showed that items 1, 4, and 5 were positive. The patient took lamivudine and the hepatitis B virus was controlled at 1.0×10 3After taking the composition of Example 1 for 2 months (the dosage is 100 g / d), the hepatitis B two-pair half quantitative test was performed again. The 2nd, 4th and 5th items of the five hepatitis B items were positive, and the other two items were negative. The patient has immunity;
[0094] 3) Patient Sun was tested for hepatitis B in the hospital and the results showed that items 1 and 5 were positive. The patient took adefovir dipivoxil and the hepatitis B virus was controlled at 1.0×10 3 After taking the composition of Example 1 for 2 months (the dosage is 200 g / d), the hepatitis B two-pair half quantitative test was performed again. The 2nd, 4th and 5th items of the five hepatitis B items were positive, and the other two items were negative. The patient has immunity;
[0095] 4) Patient Gao was tested in the hospital for five items of hepatitis B, and the first and third items were positive. After taking the composition of Example 1 for 3 months (the dosage was 200 g / d), the patient was tested for two-pair-and-a-half quantitative hepatitis B test again. The second, fourth and fifth items of the five items of hepatitis B were positive, and the remaining two items were negative. The patient already had immunity;
[0096] Therefore, it can be seen that the combination of the composition of the present invention and drugs such as lamivudine, adefovir dipivoxil or entecavir has a significant therapeutic effect on hepatitis B virus.
[0097] The dosage forms of the above-mentioned composition include but are not limited to tablets, granules, pills, powders, oral liquids, decoctions, etc.
[0098] Although the present invention has been described in detail above by general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.
Claims
1. A composition for treating hepatitis B, It is characterized in that The composition comprises the following raw materials by weight: 10-25 parts of Poria cocos, 5-15 parts of Schisandra chinensis, 5-15 parts of Atractylodes macrocephala, 15-30 parts of Herba Crepisae, 10-20 parts of Licorice, 5-15 parts of Bupleurum chinense, 15-30 parts of Astragalus membranaceus, 15-30 parts of Salvia miltiorrhiza, 10-20 parts of Angelica sinensis, 10-20 parts of Scutellaria barbata, 10-20 parts of White Peony Root, 3-8 parts of Mulberry Leaf, 3-8 parts of Pueraria lobata, 3-8 parts of Cimicifuga heracleifolia, 3-8 parts of Vitex rotundifolia, 3-8 parts of Gentiana scabra, and 9-24 parts of auxiliary materials; The auxiliary materials include 3-8 parts of powdered sugar, 3-8 parts of dextrin, and 3-8 parts of maltose; The dosage form of the composition includes but is not limited to tablets, granules, pills, powders, oral liquids, and decoctions; The preparation method of the composition includes but is not limited to the following steps: grinding the raw materials into powder, preparing the intermediate extract, separating and purifying, evaporating and drying; The preparation of the intermediate extract includes the following methods: decoction method, soaking method, permeation method, reflux method, steam method, supercritical fluid extraction method, auxiliary extraction method; The separation and purification are not limited to the following methods: solid-liquid separation method, water-alcohol method, adsorption clarification method, macroporous resin adsorption separation method, membrane separation method; The evaporation and drying include but are not limited to the following methods: normal pressure method, reduced pressure method, thin film evaporation method, reduced pressure drying, spray drying, and freeze drying.
2. The composition according to claim 1, It is characterized in that The preparation of the tablet of the composition comprises the following steps: S1: Grind all raw materials into powder; S2: Preparation of intermediate extract: add 3.5 times the amount of 95% ethanol solution to the raw material for the first time, reflux for 1.5 hours, filter, recover ethanol from the filtrate, and concentrate to an extract with a relative density of 1.35-1.39; add 5 times the amount of 50% ethanol solution to the extract for the second time, reflux for 1.5 hours, filter; add 5 times the amount of water for the third time, reflux for 2 hours, filter; combine the second and third filtrates, recover ethanol, concentrate to a relative density of 1.20, dilute with water to 0.5g / ml, let stand overnight, filter, and dry the filter residue to obtain the intermediate extract; S3: separation and purification: add 6 times the amount of 50% ethanol solution to the intermediate extract, extract 3 times, 2.5 hours each time, filter, recover ethanol from the filtrate, and when concentrated to a certain relative density, select HPD-100 macroporous adsorption resin, adjust the concentration of the loading solution to 17 mg / ml, use 80% ethanol solution as the eluent, and recover ethanol after elution; S4: evaporation and drying: the intermediate extract and an appropriate amount of auxiliary materials are mixed to form granules, dried, borneol is ground into fine powder, mixed with the granules, tableted, and coated to obtain the composition tablets.
3. The composition according to claim 2, It is characterized in that The tablets include whole raw drug powder tablets, semi-diffuse paste tablets and whole extract tablets; Grind all raw materials into medicinal powder, hereinafter referred to as medicinal powder; The preparation method of the whole raw medicinal powder tablet is as follows: The drug powder, starch, microcrystalline cellulose and low-substituted hydroxypropyl cellulose are mixed evenly, an appropriate amount of ethanol or distilled water is added as a wetting agent, and the mixture is stirred evenly to form a soft material, and the soft material is made into granules through a 14-20 mesh screen and dried until the moisture content of the granules is 3-10%, and the drying temperature is controlled at 40-100° C., and then magnesium stearate is added to the dried granules and mixed evenly, and tableting is performed to obtain the whole raw drug powder tablets; The preparation method of the semi-diffuse paste tablet is as follows: Extracting half of the drug powder with ethanol solutions of 80-95%, 50-70%, and 30-40% respectively, discarding the drug residue, and concentrating the extract under reduced pressure and drying to obtain extract powder; uniformly mixing the extract powder, the other half of the drug powder, starch, low-substituted hydroxypropyl cellulose, and microcrystalline cellulose, and tableting, sugar coating, or film coating to obtain the semi-diffuse paste tablet; The preparation method of the full extract tablet is as follows: The drug powder is extracted with ethanol solutions with concentrations of 80-95%, 50-70%, and 30-40%, respectively, and the drug residue is discarded. The extract is concentrated under reduced pressure and dried to obtain extract powder; the extract powder, starch, low-substituted hydroxypropyl cellulose, and microcrystalline cellulose are evenly mixed, and the whole extract tablets are obtained by tableting, sugar coating, or film coating.
4. The composition according to claim 1, It is characterized in that The preparation of the intermediate extract of the composition decoction comprises the following steps: Add 6 times the amount of 70% ethanol solution to the raw material, reflux extraction 3 times, each time for 1.5 hours, filter, recover ethanol from the filtrate, and when concentrated to a certain relative density, purify it with HPD-100 macroporous adsorption resin, first elute with 1BV water, then elute with 5BV30% ethanol solution, recover ethanol from the eluate, and obtain the first extract; add 12 times the amount of water, decoct and extract 3 times, each time for 0.5 hours, reduce the pressure on the decoction and concentrate it to an appropriate amount, add ethanol to make the alcohol content reach 65%, let it stand overnight, filter the filtrate, recover ethanol, and obtain the second extract; combine the above two extracts to obtain the intermediate extract of the decoction.
5. The composition according to claim 1, It is characterized in that The preparation of the intermediate extract of the oral liquid of the composition comprises the following steps: Add 12 times the amount of water to the raw material, soak for 1 hour, steam distill for 8 hours to extract volatile oil, collect the distillate, filter the distilled aqueous solution and set aside; soak the residue in water for 1 hour, decoct for 3 times, each time adding water that is 10 times the amount of the slices, and the decoction time is 1 hour, combine the decoctions, and filter; heat and reflux with 8 times the amount of 60% ethanol solution for 2 times, each time for 1 hour, filter the extract, pass the filtrate through DM-301 macroporous adsorption resin, and elute with 80% ethanol solution as an eluent, collect the eluate, recover the ethanol, combine the above filtrates, and concentrate under reduced pressure to obtain the intermediate extract of the oral liquid.
6. The composition according to claim 1, It is characterized in that The preparation of the intermediate extract of the composition pill comprises the following steps: Add 10 times the amount of water to the raw material, soak for 0.5h, then steam distill for 8h to extract volatile oil, and filter the medicinal liquid; add 6 times the amount of water to the medicinal residue after steam distillation, soak for 0.5h, and decoct for 3 times, each time for 1h; combine the extracts, filter, and concentrate the filtrate to a relative density of 1.10, add an appropriate amount of ethanol solution to make the alcohol precipitation concentration of 70%, let it stand for 8h, filter, and recover ethanol from the filtrate; the filtrate is combined with the medicinal liquid after steam distillation, concentrated to a certain volume, concentrated under reduced pressure to a certain relative density, and dried under reduced pressure to obtain the intermediate extract of the pills.
7. The composition according to claim 1, It is characterized in that The preparation method of the granules of the composition comprises the following steps: adding 1500 mg of water to the raw materials, heating to 90-200° C., steaming for 60-90 minutes, then squeezing out the juice under pressure, then collecting the paste, adding sugar powder and dextrin, stirring and drying until the moisture content of the granules is 3-30%, and the drying temperature is controlled at 40-100° C., so as to obtain the granules of the composition.
8. Use of the composition according to any one of claims 1 to 7 in the preparation of drugs for promoting the conversion of hepatitis B surface antigen to negative, hepatitis B surface antibody to positive, and core antibody for the treatment of hepatitis B.
9. The use according to claim 8, It is characterized in that The composition is used in medicine for treating an in vitro animal model for studying the mechanism of hepatitis B production.
Citation Information
Patent Citations
An oral powder for treating hepatitis B
CN102266517A
Detoxification strengthening powder for treating chronic viral hepatitis B
CN103356923A
